Research ArticleArticle
Open Access
Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
Michael E. Weinblatt, Larry W. Moreland, Rene Westhovens, Roger B. Cohen, Sheila M. Kelly, Nader Khan, Ramesh Pappu, Ingrid Delaet, Allison Luo, Sheila Gujrathi and Marc C. Hochberg
The Journal of Rheumatology April 2013, jrheum.120906; DOI: https://doi.org/10.3899/jrheum.120906
Michael E. Weinblatt
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Larry W. Moreland
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Rene Westhovens
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Roger B. Cohen
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Sheila M. Kelly
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Nader Khan
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Ramesh Pappu
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Ingrid Delaet
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Allison Luo
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Sheila Gujrathi
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
Marc C. Hochberg
From Brigham and Women’s Hospital, Boston, Massachusetts, USA; University of Pennsylvania Medical Center (UPMC) Arthritis and Autoimmunity Center, Pittsburgh, Pennsylvania, USA; Catholic University of Leuven, Leuven, Belgium; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Bristol-Myers Squibb, Princeton, New Jersey; and University of Maryland School of Medicine, Baltimore, Maryland, USA. Supported by Bristol-Myers Squibb. M.E. Weinblatt has received consulting fees and research grants from Bristol-Myers Squibb. R. Westhovens has received consulting fees from Bristol-Myers Squibb, Centocor Inc., Roche, and Schering-Plough; has participated in speaker bureaus for Bristol-Myers Squibb; and has received research grants from Roche and UCB Inc. R. Cohen has received consulting fees from Bristol-Myers Squibb. M.C. Hochberg is a consultant for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Genentech/Roche, and UCB Inc. M.E. Weinblatt, MD, Brigham and Women’s Hospital; L.W. Moreland, MD, UPMC Arthritis and Autoimmunity Center; R. Westhovens, MD, PhD, Catholic University of Leuven; R.B. Cohen, MD, Fox Chase Cancer Center; S.M. Kelly, MD; N. Khan, MD; R. Pappu, PhD; I. Delaet, PhD; A. Luo, MD; S. Gujrathi, MD, Bristol-Myers Squibb; M.C. Hochberg, MD, MPH, University of Maryland School of Medicine. Address correspondence to Dr. M.E. Weinblatt, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: mweinblatt@partners.org Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication February 8, 2013.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
Michael E. Weinblatt, Larry W. Moreland, Rene Westhovens, Roger B. Cohen, Sheila M. Kelly, Nader Khan, Ramesh Pappu, Ingrid Delaet, Allison Luo, Sheila Gujrathi, Marc C. Hochberg
The Journal of Rheumatology Apr 2013, jrheum.120906; DOI: 10.3899/jrheum.120906
Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program
Michael E. Weinblatt, Larry W. Moreland, Rene Westhovens, Roger B. Cohen, Sheila M. Kelly, Nader Khan, Ramesh Pappu, Ingrid Delaet, Allison Luo, Sheila Gujrathi, Marc C. Hochberg
The Journal of Rheumatology Apr 2013, jrheum.120906; DOI: 10.3899/jrheum.120906